GlassScriptPhysician profile
Merveen Appu
NPI 1194046193
$12,364.29
in general payments reported to CMS, 2019-2025
51 companies · $3,149 in 2025
The $3,149 reported for 2025 was more than what 82% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,618 · 2020: $671 · 2021: $1,261 · 2022: $1,872 · 2023: $1,592 · 2024: $2,202 · 2025: $3,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,943.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,449.46 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Neurelis, INC. | $1,147.91 | 2020-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $657.31 | 2022-2025 | |
| Catalyst Pharmaceuticals, INC. | $629.11 | 2023-2025 | Fycompa |
| Ptc Therapeutics, INC. | $617.72 | 2019-2024 | Emflaza |
| Ipsen Biopharmaceuticals, INC | $525.00 | 2019-2025 | Dysport |
| Livanova USA, INC. | $460.72 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Greenwich Biosciences, INC. | $411.59 | 2019-2021 | |
| Eisai INC. | $387.30 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $359.87 | 2019-2025 | Koselugo |
| Immedica Pharma US, INC. | $347.34 | 2022-2024 | |
| Biogen, INC. | $336.64 | 2019-2025 | Spinraza, Skyclarys |
| Aucta Pharmaceuticals, INC. | $334.82 | 2024-2025 | Motpoly Xr |
| Novartis Pharmaceuticals Corporation | $299.24 | 2019-2025 | |
| Zogenix INC. | $291.11 | 2020-2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merveen Appu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.